Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept 8mg in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration
NCT07728981Phase 1Not yet recruiting
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Jul 2026
- Primary completion
- Aug 2026
01
Overview
Phase 1, open-label, single-arm trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Tianjin Medical University Eye Hospital. Primary endpoint: Vascular Endothelial Growth Factor A levels in aqueous humor at 11 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07728981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07728981.